
浏览全部资源
扫码关注微信
纸质出版日期:2012
移动端阅览
邵志祥, 汤伟. 抗纤胶囊对实验性大鼠肝纤维化的治疗作用[J]. 中国实验方剂学杂志, 2012,18(11):212-215.
SHAO Zhi-xiang, TANG Wei. Therapeutic Effects of Kangxian Capsule on the Hepatic Fibrosis in Rats[J]. Chinese journal of experimental traditional medical formulae, 2012, 18(11): 212-215.
目的: 探讨抗纤胶囊对四氯化碳(CCL4)诱导的实验性大鼠肝纤维化的治疗作用。 方法: 40只雄性SD大鼠随机分为正常对照组、模型组、秋水仙碱组、抗纤胶囊高、低剂量组。除正常对照组外
各组大鼠均采用CCl4和高脂饲料复合诱导制备大鼠肝纤维化模型
同时治疗组分别每天ig抗纤胶囊 (0.637 5
0.425 g·kg-1)和秋水仙碱 (1.562 5×10-4 g·kg-1)
干预6周
对照组和模型组动物每天ig生理盐水。采用全自动生化分析仪检测血清丙氨酸氨基转移酶(ALT)、天门冬氨酸氨基转移酶(AST)活性
放射免疫法检测血清透明质酸(HA)、层粘连蛋白(LN)、Ⅲ型前胶原(PCⅢ)的含量
光镜下观察肝组织病理改变。 结果: 模型组大鼠肝组织内肝细胞广泛变性及坏死
大量炎性细胞浸润
类假小叶形成
大量胶原纤维形成;抗纤胶囊治疗组的肝脏病理变化程度较模型组明显减轻且无类假小叶形成。抗纤胶囊(0.637 5
0.425 g·kg-1)组的ALT和AST活性为(70.88±20.66)
(86.25±22.05) U·L-1
(131.50±31.52)
(151.25±38.66) U·L-1;抗纤胶囊(0.637 5
0.425 g·kg-1)组的HA
LN
PCⅢ的含量为(340.93±64.75)
(363.88±80.44)ng·L-1
(261.59±56.93)
(311.84±61.60) ng·L-1
(61.67±14.51)
(76.47±19.68)μg·L-1
与模型组比较
抗纤胶囊治疗组大鼠的血清ALT
AST
HA
LN
PCⅢ水平显著降低(P<0.01)。 结论: 抗纤胶囊对CCL4诱导的大鼠具有较好的抗肝纤维化作用。
Objective: To study the therapeutic effects of Kangxian capsule
a Chinese patent medicine
on the hepatic fibrosis in rats. Method: Forty male SD rats were randomly divided into normal control group
model group
colchicine group
Kangxian capsule high dose and low dose group. In order to prepare the hepatic fibrosis model
all the rats except those of the normal control group were subcutaneously administrated with the CCL4 olive oil solution for six weeks and were given high-fat diet in the first two weeks. The treatment groups were given different doses of Kangxian capsule and colchicine intervention for six weeks. The control group and model group animals were intragastrically fed with the same volume of normal saline. The activities of alanine aminotransferase(ALT) and aspartate aminotransferase(AST) in rat sera were detected with automatic biochemistry analyzer. The concentrations of hyaluronic(HA)
laminin(LN)
typeⅢ procollagen (PCⅢ)in sera were measured with the method of radioimmunoassay.The pathohistological changes were observed under microscope. Result: Compared with the model group
the serum levels of ALT
AST
HA
LN
PCⅢ in rats of Kangxian capsule treatment groups were significantly lower(P<0.01).There were much degeneration and necrosis
inflammatory cell infiltration
false lobular formation
and a large number of collagen fiber depositions in liver tissue of the model group. Compared with the model group
the level of chronic hepatic damage was improved greatly and none of the false lobular formed in two dose of Kangxian capsule groups. Conclusion: Kangxian capsule can greatly protect from hepatic fibrosis in rats induced by CCL4.
0
浏览量
3
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621